engineered interleukin 8 (IL‐8) receptors CXCR1 or CXCR2 in αvβ6‐targeted CAR T‐cells and demonstrated the superior anti‐tumour activity of these armed CAR‐T cells against established αvβ6‐expressing ovarian or pancreatic tumour xenografts.18 The gene discussed is CXCL8; the disease is pancreatic neoplasm.